Welcome to LUCIRA® Connect
Emergency Use Authorization only*
If you don’t have a healthcare professional or your healthcare professional isn’t available, these resources may help you connect with an in-person or telehealth provider.
Pfizer does not own, operate, or endorse any of these telehealth platforms, or the services they or their providers may furnish, and Pfizer accepts no responsibility or liability for them.
Telehealth vendors were selected based on their ability to provide services via telehealth. Neither the providers nor the telehealth platforms pay a fee to Pfizer for inclusion on this website.
If these telehealth platforms match users with providers, the selection of a particular provider is determined by the criteria set by the platform and/or provider, not Pfizer. All treatment decisions are at the sole discretion of the provider based on the patient’s individual needs and risk-benefit profile.
*By clicking these links, you will be redirected to a website that is neither owned nor controlled by Pfizer. Pfizer is not responsible for the content or services of these sites.
†By clicking this link, you will be redirected to a website that is owned and controlled by a third party Ada Health Inc. Pfizer Inc. has contracted with Ada Health Inc. for the development, hosting, and operation of this platform.
Emergency Use Authorization
LUCIRA® by Pfizer COVID-19 & Flu Home Test has not been FDA cleared or approved but has been authorized for emergency use by FDA under an Emergency Use Authorization (EUA). It has been authorized only for the detection and differentiation of nucleic acid from SARS-CoV-2, influenza A, and influenza B, not for any other viruses or pathogens. This authorization is for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated, or authorization is revoked sooner.
Intended for simultaneous rapid in vitro qualitative detection and differentiation of SARS-CoV-2, influenza A, and influenza B viral nucleic acid. This test is authorized for nonprescription home use with anterior nasal swab samples from individuals 14 years or older (self-collected) or individuals 2 years or older (collected by an adult) with signs and symptoms consistent with a respiratory tract infection, including COVID-19.
Please see product authorized labeling at https://www.lucirapfizer.com/labeling